|
- CALCIFEDIOL SOFT CAPSULES - European Patent Office - EP 3204047 B1
Description FIELD OF THE INVENTION [0001] The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, and to their process of manufacture
- EP3053598A1 - Calcifediol soft capsules - Google Patents
Prior art immediate release calcifediol pharmaceutical preparations for oral administration having suitable bioavailability are those marketed under the name Hidroferol® (Faes Farma), wherein
- CALCIFEDIOL SOFT CAPSULES - Patent 3689380
One example of such a formulation is a solution consisting of calcifediol (0 266 mg; 15,960 IU calcifediol), medium chain triglycerides (1 5 ml) and α-tocopherol acetate (0 266; vitamin E acetate)
- EP-3689380-B1 - Calcifediol Soft Capsules | Unified Patents
You can ask me any questions related to the content of the patent you're currently viewing Whether it's about the inventor, claims, abstract, or any other specific section
- EP3204047A1 - Calcifediol soft capsules - Google Patents
The present invention relates to calcifediol soft capsules, to their use in the treatment or prevention of diseases related to vitamin D deficiency, such as vitamin D deficiency,
- Drug Patents containing Calcifediol - pharsight. greyb. com
Given below is the list of patents protecting Calcifediol, along with the drug name that holds that patent and the company name owning that drug A patent's expiry date may change depending upon legal activities going on that patent
- Calcifediol soft capsules - Patent 3053598
[0011] The authors of the present invention have found a calcifediol immediate release oral formulation having improved bioavailability with respect to a liquid calcifediol immediate release oral formulation of the prior art (i e , Hidroferol®)
- CALCIFEDIOL SOFT CAPSULES - European Patent Office - EP 3689380 A1
Other types of calcifediol oral formulations have been described, such as controlled release solid formulations comprising calcifediol (WO 2007 092755), wherein the active compound is provided within a wax matrix that releasably binds the drug
|
|
|